{
    "clinical_study": {
        "@rank": "164708", 
        "arm_group": {
            "arm_group_label": "PMK-S005", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The Purpose of a randomized, double-blind, placebo-controlled, single-dose, dose-escalation\n      clinical trial is to explore investigate the safety, tolerability, pharmacokinetics, and\n      food effect of PMK-S005 after oral administration in healthy male volunteers."
        }, 
        "brief_title": "A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers", 
        "condition": [
            "Gastritis", 
            "Gastric Ulcer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gastritis", 
                "Stomach Ulcer", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male 20 year \u2264 age \u2264 40 year.\n\n          -  Weight \u2265 55kg, IBW \u00b120%.\n\n          -  Patients with normal hematology, biochemistry, urinary result.\n\n          -  Patients who have not congenital or chronic disease.\n\n          -  Provision of written informed consent voluntarily.\n\n        Exclusion Criteria:\n\n          -  Patients having known hypersensitivity to any component of the study drug.\n\n          -  Patients with a history of abnormal digestive organ, kidney, respiratory,\n             neuroendocrine, cardiovascular, hemato-oncology, urinary, muscloskeletal, immune, the\n             nose and ears, psychiatry, stomach system.\n\n          -  Patients with any gastrointestinal disorders.\n\n          -  Systolic blood pressure \u2265 150 or \u2264 90 mmHg, Diasolic blood pressure \u2265 95 or \u2264 50\n             mmHg.\n\n          -  Drug abuser, alcoholic.\n\n          -  Patients taking ETC medication within 14 days, OTC within 7 days.\n\n          -  Patients taking other investigational product within 60 days prior to the\n             participation in the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01762397", 
            "org_study_id": "PMK-S005"
        }, 
        "intervention": {
            "arm_group_label": "PMK-S005", 
            "intervention_name": "PMK-S005", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daejeon", 
                    "country": "Korea, Republic of", 
                    "state": "Chungnam", 
                    "zip": "301-721"
                }, 
                "name": "Chungnam national university hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse Event: symptom, start day and time, end day and time, injection time, severity, progress, outcome, relation with investigational product.\nBefore and after physical examination\nBefore and after bital Sign: blood pressure, pulse rate, temperature.\nBefore and after 12-ECG: ventricular rate (/min), PR interval (msec), QRS duration (msec), QT/QTc interval (msec.\nLab: hematologic examination, blood coagulation examination,urine examination", 
                "measure": "Safety", 
                "safety_issue": "No", 
                "time_frame": "8day"
            }, 
            {
                "description": "Blood evaluation variables: Cmax, AUCt (t=48 h), AUC\u221e, tmax, CL/F, t1/2.\nUrine evaluation variables: Aet (t=48 h), Ae\u221e, urine recovery", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "8day"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01762397"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "PharmaKing", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PharmaKing", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}